The Board has determined that the Veteran's AIP and Type I Diabetes Mellitus were not caused or aggravated by VA care, specifically his Whipple procedure in August 2005. The decision is denied.
The deciding factor: The medical opinions provided indicate that the Whipple procedure was the correct treatment for the presumed diagnosis of carcinoma in the pancreas, and there was no reasonable alternative therapy available at the time. The AIP was found to be a primary condition unrelated to VA care, while the Type I Diabetes Mellitus is considered secondary.
- Claimed conditions
- Autoimmune Pancreatitis (AIP), Type I Diabetes Mellitus
- How they argued it
- Direct service connection
- Exposure basis
- None
- Rating assigned
- None in this decision
- Decision date
- March 25, 2024
- Citation
- A24013840
This is a plain-language summary generated by AI from a public Board of Veterans’ Appeals decision. It can contain errors — always verify against the original. Look up the original decision on VA.gov (opens in a new tab) using citation A24013840.
What this means for you
A denial is a starting point, not the end of the road. You can see why this claim fell short — and, if you are still inside the one-year window, the appeal lanes that may remain open to you.
What you can do next
Related decisions
Other Board decisions on a similar condition or argued the same way.
- Denied
The Board denied service connection for autoimmune pancreatitis (AIP) as there is no evidence that it was incurred during or related to the Veteran's military service, including his exposure to environmental toxins in Southwest Asia.
- Remanded (sent back)
The Veteran's diabetes mellitus with nephropathy and erectile dysfunction required more than one daily injection of insulin, restricted diet, and regulation of activities prior to January 25, 2021. The Board has remanded the issues related to a respiratory disorder secondary to his service-connected conditions.
- Granted
The Veteran's type I diabetes mellitus is currently rated at 20 percent, which is the maximum schedular rating available.,Prior to August 12, 2015, the Veteran's bilateral proliferative diabetic retinopathy with retinal bleed and pseudophakia was rated at 30 percent. From August 12, 2015, it has been rated at 40 percent.,The Veteran's bilateral proliferative diabetic retinopathy with retinal bleed and pseudophakia is currently rated at the maximum schedular rating of 40 percent.
- Remanded (sent back)
The Board has remanded the Veteran's claims for service connection for Type I Diabetes Mellitus and Right Foot Condition due to inadequate examination and lack of contemporaneous medical evidence.
Free starter guide for your own claim
Reading this because you were denied or under-rated? Get the plain-English next steps — your appeal options, the deadline that protects you, and how appeals like yours turn out. One email, no spam.
We will only use this to send the guide. No spam, unsubscribe any time. We never sell your information.
We are not the VA. Veterans’ Rights is an independent resource built for veterans. We are not the U.S. Department of Veterans Affairs, not part of the government, and not endorsed by any government agency.
This is general information, not legal advice. For advice about your own situation, talk to a VA-accredited representative — many help for free.